GLP1R and type 2 diabetes mellitus: (glucagon-like peptide-1 receptor agonist OR GLP-1 agonist) AND (type 2 diabetes OR T2DM) AND ((MACE) OR [major adverse cardiovascular events] OR (cardiovascular outcomes) OR (myocardial infarction) OR (Renal failure))